ストックスクリーナーアプリを入手
16.81
10.45%
1.59
前日終値:
$15.22
開ける：
$16.09
24時間の取引高:
130.92K
Relative Volume:
1.97
時価総額：
$174.08M
収益：
$88.50M
当期純損益:
$-35.27M
株価収益率:
-5.101
EPS:
-3.2954
ネットキャッシュフロー:
$-23.70M
1週間 パフォーマンス:
+13.58%
1か月 パフォーマンス:
+17.96%
6か月 パフォーマンス:
+136.76%
1年 パフォーマンス:
+204.31%
1日の値動き範囲:
$15.26
$17.40
1週間の範囲:
$14.81
$17.40
52週間の値動き範囲:
$5.00
$20.21
Biodesix Inc Stock (BDSX) Company Profile
Compare BDSX vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
16.81 | 174.08M | 88.50M | -35.27M | -23.70M | -3.2954 |
TMO
Thermo Fisher Scientific Inc
|
464.61 | 172.66B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.17 | 125.40B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.09 | 44.34B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
127.06 | 35.89B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
355.44 | 34.90B | 3.77B | 449.25M | 240.68M | 7.8556 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-27 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-05-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-26 | 開始されました | Craig Hallum | Buy |
| 2024-05-13 | 開始されました | TD Cowen | Buy |
| 2024-05-03 | 開始されました | Lake Street | Buy |
| 2021-11-17 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 開始されました | BTIG Research | Buy |
| 2020-11-23 | 開始されました | Canaccord Genuity | Buy |
| 2020-11-23 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-23 | 開始されました | William Blair | Outperform |
すべてを表示
Biodesix Inc (BDSX) 最新ニュース
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains? - Yahoo Finance Singapore
Soleus discloses 525,241-share (5.1%) stake in Biodesix (BDSX) - Stock Titan
Canaccord raises Biodesix stock price target to $27 on growth outlook By Investing.com - Investing.com Australia
Canaccord raises Biodesix stock price target to $27 on growth outlook - Investing.com
Biodesix Inc (BDSX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biodesix Inc (BDSX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biodesix Inc (BDSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biodesix Inc (BDSX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biodesix Inc (BDSX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biodesix Inc (BDSX) Institutional Confidence - TradingKey
BDSX Technical Analysis & Stock Price Forecast - Intellectia AI
Biodesix Inc (BDSX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biodesix Inc (BDSX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Biodesix Inc (BDSX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BDSX Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
Are Medical Stocks Lagging Biodesix (BDSX) This Year? - Yahoo Finance
HC Wainwright Initiates Biodesix at Buy With $26 Price Target - marketscreener.com
Biodesix, Inc. (BDSX) reports Q1 loss, tops revenue estimates - MSN
BDSX Q1 2026 Earnings: EPS Beat on Lower-Than-Expected Loss; Stock Dips SlightlyLow Growth Earnings - newsline.com
BDSX Q1 2026 Earnings: EPS Surpasses Estimates Despite Net Loss, Stock Ticks DownEarnings Turnaround - newsline.com
Biodesix (BDSX) Tests Resistance After Modest Gain Amid Sector VolatilityVWAP Deviation - newsline.com
Biodesix Inc. (BDSX) Shows Resilience: Shares Gain 2.08% Amid Sector InterestAccumulation Line - newsline.com
Zacks Industry Outlook Highlights BrightSpring Health Services, Biodesix and HealthEquity - sharewise.com
BDSX News | BIODESIX INC (NASDAQ:BDSX) - ChartMill
Biodesix Q1 2026 Earnings: EPS Surprise Beats Estimates by 27.5% Amid Revenue Disclosure GapHigh Growth Earnings - newsline.com
[EFFECT] BIODESIX INC SEC Filing - Stock Titan
BDSX Stock Price, Quote & Chart | BIODESIX INC (NASDAQ:BDSX) - ChartMill
Biodesix Inc. (BDSX) Climbs 2% as Stock Tests Key Resistance Near $17.14Iron Condor Alert - newsline.com
Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biodesix (NASDAQ: BDSX) registers resale of 375,000 shares - Stock Titan
Biodesix (BDSX) Gains 1.43% as Shares Test Resistance Near $17New Highs New Lows - The Legal Advocate
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance
BDSX Q1 2026 Earnings: EPS Beats Estimates by 27.54% Amid Cost DisciplineEarnings Cycle Report - newsline.com
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade - Zacks Investment Research
Biodesix Inc. (BDSX) Q1 2026 Earnings: Strong EPS Beat Overshadowed by Negative Stock ReactionFinal Results - newsline.com
Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions - Insider Monkey
Biodesix (NASDAQ: BDSX) registers 375,000 shares for Perceptive resale - Stock Titan
Biodesix shareholders elect directors and approve executive compensation By Investing.com - Investing.com South Africa
Biodesix to Participate in Upcoming Investor Conferences - The Manila Times
Biodesix meets investors in Minneapolis, Chicago and Dana Point - Stock Titan
Biodesix shareholders elect directors and approve executive compensation - Investing.com India
Biodesix Shareholders Approve Directors and Governance Measures - TipRanks
Biodesix (NASDAQ: BDSX) holders back directors, pay and KPMG auditor - Stock Titan
Perceptive entities disclose 4.6% holding in Biodesix (NASDAQ: BDSX) - Stock Titan
Biodesix BDSX Q2 2025 Earnings Call Transcript - AOL.com
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy - The Manila Times
Blood test for lung nodules gets real-world spotlight at ATS 2026 - Stock Titan
BDSX Biodesix shifts focus to lung health diagnostics, CEO signals confidence in breakthrough testing pipeline despite sector volatility.Pre-Earnings Setup - newsline.com
Does Biodesix (BDSX) have the potential to rally 103.33% as Wall Street analysts expect? - MSN
Biodesix Inc (BDSX) 財務データ
収益
当期純利益
現金流量
EPS
1.40%
1.36%
大文字化:
|
ボリューム (24 時間):